Ironwood Pharmaceuticals (IRWD) EBIAT (2016 - 2025)
Historic EBIAT for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $40.1 million.
- Ironwood Pharmaceuticals' EBIAT rose 99928.69% to $40.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.5 million, marking a year-over-year increase of 101473.89%. This contributed to the annual value of $880000.0 for FY2024, which is 10008.53% up from last year.
- Ironwood Pharmaceuticals' EBIAT amounted to $40.1 million in Q3 2025, which was up 99928.69% from $23.6 million recorded in Q2 2025.
- In the past 5 years, Ironwood Pharmaceuticals' EBIAT ranged from a high of $391.3 million in Q2 2021 and a low of -$1.1 billion during Q2 2023
- In the last 5 years, Ironwood Pharmaceuticals' EBIAT had a median value of $37.1 million in 2022 and averaged -$15.8 million.
- Per our database at Business Quant, Ironwood Pharmaceuticals' EBIAT tumbled by 303818.23% in 2023 and then skyrocketed by 284406.98% in 2025.
- Ironwood Pharmaceuticals' EBIAT (Quarter) stood at $41.4 million in 2021, then increased by 18.11% to $48.9 million in 2022, then tumbled by 103.57% to -$1.7 million in 2023, then soared by 229.28% to $2.3 million in 2024, then soared by 1676.6% to $40.1 million in 2025.
- Its EBIAT was $40.1 million in Q3 2025, compared to $23.6 million in Q2 2025 and -$37.4 million in Q1 2025.